Furthermore, the data presented in this study reveal that NQO1 and the NQO1:CAT ratio could be used as biomarkers to examine the efficacy of NQO1 bioactivatable drugs in HCC or other kinds of liver cancers. This evidence concerns the gene CAT and hepatocellular carcinoma.